<?xml version='1.0' encoding='utf-8'?>
<document id="27052428"><sentence text="Evaluation of pharmacokinetic interactions between long-acting HIV-1 fusion inhibitor albuvirtide and lopinavir/ritonavir, in HIV-infected subjects, combined with clinical study and simulation results."><entity charOffset="102-111" id="DDI-PubMed.27052428.s1.e0" text="lopinavir" /><entity charOffset="112-121" id="DDI-PubMed.27052428.s1.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.27052428.s1.e0" e2="DDI-PubMed.27052428.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27052428.s1.e0" e2="DDI-PubMed.27052428.s1.e1" /></sentence><sentence text="1" /><sentence text=" A clinical study to assess the interactions between albuvirtide (320 mg) and lopinavir/ritonavir (400/100 mg) was conducted in 10 HIV-1-infected subjects"><entity charOffset="78-87" id="DDI-PubMed.27052428.s3.e0" text="lopinavir" /><entity charOffset="88-97" id="DDI-PubMed.27052428.s3.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.27052428.s3.e0" e2="DDI-PubMed.27052428.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27052428.s3.e0" e2="DDI-PubMed.27052428.s3.e1" /></sentence><sentence text=" Because albuvirtide requires a long period to achieve steady state, and extended monotherapy may lead to early resistance, it is unethical to take albuvirtide alone to achieve steady state" /><sentence text=" Therefore, a population pharmacokinetic model was developed to predict steady-state concentration-time curve of solely administered albuvirtide" /><sentence text=" 2" /><sentence text=" When albuvirtide and lopinavir/ritonavir were co-administered, the plasma concentration of albuvirtide when the infusion ended (Cend) increased by about 34%, but the geometric mean ratios and 90% confidence intervals (90% CIs) of AUC(0-t) [1"><entity charOffset="6-17" id="DDI-PubMed.27052428.s7.e0" text="albuvirtide" /><entity charOffset="22-31" id="DDI-PubMed.27052428.s7.e1" text="lopinavir" /><entity charOffset="32-41" id="DDI-PubMed.27052428.s7.e2" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.27052428.s7.e0" e2="DDI-PubMed.27052428.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27052428.s7.e0" e2="DDI-PubMed.27052428.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27052428.s7.e0" e2="DDI-PubMed.27052428.s7.e2" /><pair ddi="false" e1="DDI-PubMed.27052428.s7.e1" e2="DDI-PubMed.27052428.s7.e1" /><pair ddi="false" e1="DDI-PubMed.27052428.s7.e1" e2="DDI-PubMed.27052428.s7.e2" /></sentence><sentence text="09 (0" /><sentence text="96-1" /><sentence text="24)] and Ctrough [1" /><sentence text="00 (0" /><sentence text="83-1" /><sentence text="20)] were within the range of 0" /><sentence text="8-1" /><sentence text="25" /><sentence text=" For lopinavir, the ratios (90% CIs) of AUC(0-t), Cmax and Ctrough were 0"><entity charOffset="5-14" id="DDI-PubMed.27052428.s16.e0" text="lopinavir" /></sentence><sentence text="63 (0" /><sentence text="49-0" /><sentence text="82), 0" /><sentence text="67 (0" /><sentence text="53-0" /><sentence text="86) and 0" /><sentence text="65 (0" /><sentence text="46-0" /><sentence text="91); for ritonavir, those ratios (90% CIs) were 0"><entity charOffset="9-18" id="DDI-PubMed.27052428.s25.e0" text="ritonavir" /></sentence><sentence text="62 (0" /><sentence text="42-0" /><sentence text="91), 0" /><sentence text="61 (0" /><sentence text="38-0" /><sentence text="99) and 0" /><sentence text="72 (0" /><sentence text="40-1" /><sentence text="26), respectively" /><sentence text=" 3" /><sentence text=" Co-administration of albuvirtide with lopinavir/ritonavir has little effect on albuvirtide exposure, but it decreases the plasma exposures of lopinavir/ritonavir"><entity charOffset="39-48" id="DDI-PubMed.27052428.s36.e0" text="lopinavir" /><entity charOffset="49-58" id="DDI-PubMed.27052428.s36.e1" text="ritonavir" /><entity charOffset="143-152" id="DDI-PubMed.27052428.s36.e2" text="lopinavir" /><entity charOffset="153-162" id="DDI-PubMed.27052428.s36.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.27052428.s36.e0" e2="DDI-PubMed.27052428.s36.e0" /><pair ddi="false" e1="DDI-PubMed.27052428.s36.e0" e2="DDI-PubMed.27052428.s36.e1" /><pair ddi="false" e1="DDI-PubMed.27052428.s36.e0" e2="DDI-PubMed.27052428.s36.e2" /><pair ddi="false" e1="DDI-PubMed.27052428.s36.e0" e2="DDI-PubMed.27052428.s36.e3" /><pair ddi="false" e1="DDI-PubMed.27052428.s36.e1" e2="DDI-PubMed.27052428.s36.e1" /><pair ddi="false" e1="DDI-PubMed.27052428.s36.e1" e2="DDI-PubMed.27052428.s36.e2" /><pair ddi="false" e1="DDI-PubMed.27052428.s36.e1" e2="DDI-PubMed.27052428.s36.e3" /><pair ddi="false" e1="DDI-PubMed.27052428.s36.e2" e2="DDI-PubMed.27052428.s36.e2" /><pair ddi="false" e1="DDI-PubMed.27052428.s36.e2" e2="DDI-PubMed.27052428.s36.e3" /></sentence><sentence text=" However, the drug-drug interactions may not reduce the effectiveness of this co-therapy, the trough concentration of lopinavir may be sufficient and this combination could achieve similar clinical efficacy with marketed drugs"><entity charOffset="118-127" id="DDI-PubMed.27052428.s37.e0" text="lopinavir" /></sentence><sentence text=" So, a phase 3 clinical trial without dose adjustment is underway to validate their effectiveness and safety" /><sentence text="" /></document>